SK Biopharmaceuticals selected 31 companies to reside in Lynx, a win-win platform in the U.S.

SK Biopharmaceuticals [326030] announced on the 9th that it has selected 31 US SK Life Science LinX companies and will provide full-scale support for their entry into the US market.

Of the 31 Lynx tenants, 14 are pharmaceutical companies, 8 are digital healthcare companies, 6 are platform companies, and 3 are medical device companies.

Lynx is an open innovation platform built by SK Biopharmaceuticals to support the entry and growth of domestic pharmaceutical and bio companies into the U.S. market, and was set up in the office of SK Life Science, a U.S. subsidiary, in June.

SK Biopharm supports tenant companies to discover business opportunities in the United States and expand their local network based on a local infrastructure of 160 pyeong.

In addition, it will provide expert advice and help with local settlement in connection with the 'K-Bio Global Innovation Lynx' consortium led by the Korea Trade-Investment Promotion Agency (KOTRA).

Lee Dong-hoon, CEO of SK Biopharm, said, “Through Lynx, we will share SK Biopharm’s experience with domestic companies and expand practical support so that each company’s technology can lead to local partners and business opportunities.”